---
title: "Stelara (ustekinumab), all indications: Safety questions"
description: "Safety questions on Stelara (ustekinumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Side effects, and Vaccines. Questions: Does Stelara raise the risk of mycobacterial or Salmonella infections? What are the contraindications for Stelara? Can Stelara cause serious allergic reactions? Can Stelara cause PRES (posterior reversible encephalopathy syndrome)? 4 further questions follow. 8 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/stelara/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Stelara (ustekinumab), all indications: Safety questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Stelara](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis)

## Warnings

<a id="stelara-particular-infections"></a>

### Does Stelara raise the risk of mycobacterial or Salmonella infections?

> “Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to 
> disseminated infections from mycobacteria (including nontuberculous, environmental 
> mycobacteria), salmonella (including nontyphi strains), and Bacillus Calmette-Guerin 
> (BCG) vaccinations. Serious infections and fatal outcomes have been reported in 
> such patients.
> It is not known whether patients with pharmacologic blockade of IL-12/IL-23 
> from treatment with STELARA may be susceptible to these types of infections. 
> Consider appropriate diagnostic testing, (e.g., tissue culture, stool culture, as 
> dictated by clinical circumstances).”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

<a id="stelara-contraindications"></a>

### What are the contraindications for Stelara?

> “STELARA is contraindicated in patients with clinically significant hypersensitivity 
> to any ustekinumab product or to any of the excipients in STELARA [see Warnings 
> and Precautions (5.5)].”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

<a id="stelara-allergic-reactions"></a>

### Can Stelara cause serious allergic reactions?

> “Serious hypersensitivity reactions, including anaphylaxis and angioedema, have 
> been reported with STELARA in clinical trials and postmarketing. Some serious 
> hypersensitivity reactions have occurred during the first intravenous dose of 
> STELARA [see Adverse Reactions (6.1, 6.2)].
> If a severe or clinically significant hypersensitivity reaction occurs, discontinue STELARA 
> immediately and initiate appropriate medical treatment [see Contraindications (4)].”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

> “Immune system disorders: Hypersensitivity reactions (e.g., anaphylaxis, 
> angioedema, dyspnea, rash, urticaria), including a fatal case that presented with 
> chest tightness and dyspnea during infusion of the first dose. Some cases of serious 
> hypersensitivity reactions have been reported in patients with a history of alpha-
> gal syndrome, allergy to mammalian meat or meat products, or anti-alpha-gal IgE. 
> In most of these cases the reactions occurred at the time of initial administration.”

Source: [STELARA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=6)

Note: Stelara is given intravenously only as the induction dose for Crohn's disease and ulcerative colitis; plaque psoriasis dosing is subcutaneous.

<a id="stelara-pres"></a>

### Can Stelara cause PRES (posterior reversible encephalopathy syndrome)?

> “Two cases of posterior reversible encephalopathy syndrome (PRES), also known 
> as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported 
> in clinical trials. Cases have also been reported in postmarketing experience 
> in patients with psoriasis, psoriatic arthritis, and Crohn’s disease. Clinical 
> presentation included headaches, seizures, confusion, visual disturbances, 
> and imaging changes consistent with PRES a few days to several months after 
> ustekinumab initiation. A few cases reported latency of a year or longer. Patients 
> recovered with supportive care following withdrawal of ustekinumab.
> Monitor all patients treated with STELARA for signs and symptoms of PRES. If PRES 
> is suspected, promptly administer appropriate treatment and discontinue STELARA.”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

> “One Case of Posterior Reversible Encephalopathy Syndrome (PRES) occurred during adult plaque psoriasis clinical studies.”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=One%20Case%20of%20Posterior%20Reversible,adult%20plaque%20psoriasis%20clinical%20studies.)

<a id="stelara-noninfectious-pneumonia"></a>

### Can Stelara cause noninfectious pneumonia?

> “Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing 
> pneumonia have been reported during post-approval use of STELARA. Clinical 
> presentations included cough, dyspnea, and interstitial infiltrates following one to 
> three doses. Serious outcomes have included respiratory failure and prolonged 
> hospitalization. Patients improved with discontinuation of therapy and in certain 
> cases administration of corticosteroids. If diagnosis is confirmed, discontinue 
> STELARA and institute appropriate treatment [see Adverse Reactions (6.2)].”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

## Side effects

<a id="stelara-pustular-erythrodermic-psoriasis"></a>

### Can Stelara cause pustular or erythrodermic psoriasis?

> “The following adverse reactions have been reported during post-approval use 
> of STELARA. Because these reactions are reported voluntarily from a population 
> of uncertain size, it is not always possible to reliably estimate their frequency or 
> establish a causal relationship to STELARA exposure.”

Source: [STELARA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=6)

> “Skin reactions: Pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis.”

Source: [STELARA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=6)

## Vaccines

<a id="stelara-vaccines"></a>

### Can patients on Stelara get live vaccines?

> “Prior to initiating therapy with STELARA, patients should receive all age-
> appropriate immunizations as recommended by current immunization guidelines. 
> Patients being treated with STELARA should avoid receiving live vaccines. Avoid 
> administering BCG vaccines during treatment with STELARA or for one year prior 
> to initiating treatment or one year following discontinuation of treatment. Caution 
> is advised when administering live vaccines to household contacts of patients 
> receiving STELARA because of the potential risk for shedding from the household 
> contact and transmission to patient.
> Non-live vaccinations received during a course of STELARA may not elicit an 
> immune response sufficient to prevent disease.”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

## Safety

<a id="stelara-report-side-effect"></a>

### How do I report a Stelara side effect?

> “To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 
> 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”

Source: [STELARA: Prescribing information, page 1, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=1)

> “You can also report a side effect or product complaint of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.”

Source: [STELARA: Medical Information Center, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/medical-information-center-professional-product-sites/#:~:text=You%20can%20also%20report%20a,Visit%20www.fda.gov%2Fmedwatch%20or%20call%201%2D800%2DFDA%2D1088.)

## Related pages
- [Medical information: Stelara (ustekinumab): All indications](https://www.evicenter.com/medical-information/stelara)
- [Indication](https://www.evicenter.com/medical-information/stelara/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/stelara/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/stelara/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/stelara/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/stelara/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/stelara/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/stelara/access-and-coverage)
